Trial Profile

Endostatin in combination with docetaxel for patients with NSCLC who resistant to the prior EGFR-TKI agent treatment.

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 24 May 2012

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Endostatin (Primary) ; Docetaxel
Indications Non-small cell lung cancer
Focus Adverse reactions; Therapeutic Use
Acronyms EnDOC

Most Recent Events

21 May 2012 Actual end date (Dec 2010) added as reported by Chinese Clinical Trial Register record.
24 Jan 2012 Status changed from recruiting to completed as reported by Chinese Clinical Trial Register record (ChiCTR-ONC09000355).
29 Dec 2011 Additional trial acronym (EnDOC) identified as reported by Chinese Clinical Trial Register record.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com